Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Non-implant valve repair for calcific aortic stenosis: the Leaflex study.

ABSTRACT:

SUBMITTER: Baumbach A

PROVIDER: S-EPMC9724929 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature

ACCESS DATA

Json Xml

Publications

Non-implant valve repair for calcific aortic stenosis: the Leaflex study.

Baumbach Andreas A Mylotte Darren D Hildick-Smith David D Kennon Simon S Jonas Michael M Bartus Krzysztof K Trebacz Jaroslaw J Halevi Rotem R Kislev Yael Y Plotnikov Lena L Andreka Peter P

EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology 20210301 16

PMID: 32928713

Similar Datasets

GWAS on Calcific Aortic Valve Stenosis

Project description:GWAS on Calcific Aortic Valve Stenosis

| PRJNA420788 | ENA

GWAS on Calcific Aortic Valve Stenosis

Project description:GWAS on Calcific Aortic Valve Stenosis

| PRJNA420787 | ENA

Cerebral Ischemic Lesions after Transcatheter Aortic Valve Implantation in Patients with Non-Calcific Aortic Stenosis.

Project description: Not available

| S-EPMC9655232 | biostudies-literature

Metabolomics Characterization of Human Calcific Aortic Valve Stenosis

Project description:BACKGROUND: Calcific aortic valve stenosis (CAVS) is the most prevalent valvular heart disease in developed countries with significant morbidity and mortality. Given the poor understanding of the pathophysiological processes leading to CAVS, we utilized a joint non-targeted metabolomics and targeted lipidomics approach to better characterize the metabolic perturbations involved in its development and progression.METHODS: We collected human aortic valve tissue from 106 patients undergoing aortic valve replacement surgery. Our cohort represented aortic valvular hemodynamics from mild to severe aortic stenosis with varying degrees of valvular calcification.RESULTS: Seventy-two significantly differential (p<0.01) metabolites across different stages of CAVS severity were filtered and identified from the tissue metabolome. Each stage of valvular stenosis was characterized by a distinct metabolic signature. The top three perturbed metabolic pathways in the setting of CAVS involved glycerophospholipid metabolism, linoleic acid metabolism and primary bile acid biosynthesis. The lysophosphatidic acid species (LysoPA) exhibited significant (p<0.05) association with CAVS severity and were also found to select patients with accelerated rate of CAVS progression. Two LysoPA species namely, 18:2 LysoPA and 20:4 LysoPA, exhibited potential to serve as biomarkers of CAVS severity.CONCLUSIONS: The present study reports the largest and most comprehensive metabolomics analysis of human aortic valve stenosis that highlights the dysregulated LysoPA pathway involved in the pathogenesis of CAVS.

2020-02-03 | MTBLS1267 | MetaboLights

Role for Galectin-3 in Calcific Aortic Valve Stenosis.

Project description: Not available

| S-EPMC5210369 | biostudies-literature

Antiphospholipid antibodies in patients with calcific aortic valve stenosis.

Project description: Not available

| S-EPMC9977117 | biostudies-literature

Lipoprotein(a) and oxidized phospholipids in calcific aortic valve stenosis.

Project description: Not available

| S-EPMC4956483 | biostudies-literature

Hutchinson-Gilford progeria syndrome with severe calcific aortic valve stenosis.

Project description: Not available